Home
Leads Biolabs

Leads Biolabs Market Share Analysis for June 2026

维立志博成立于2012年，是一家处于临床阶段的生物科技公司，致力于创新疗法的发现、开发及商业化，重点解决PD-1/PD-L1抗体为代表的现有疗法不能治疗的疾病，以满足中国及全球在肿瘤、自身免疫性疾病及其他重大疾病方面未获满足的医疗需求。

Industry: N/A

Domainleadsbiolabs.com

Year Founded--

Employees51 - 200

Annual Revenue--

Leads Biolabs

Leads Biolabs (including company regionals)

leadsbiolabs.com

See more website traffic and engagement information

Total visits to Leads Biolabs's top domains

Understand Leads Biolabs market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

leadsbiolabs.com--

See more with Sales Intelligence

Avg. visit duration in Leads Biolabs's top domains

Analyze Leads Biolabs engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

leadsbiolabs.com--

See more with Sales Intelligence

Avg. pageviews on Leads Biolabs's top domains

See how Leads Biolabs keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

leadsbiolabs.com--

See more with Sales Intelligence

Leads Biolabs top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Leads Biolabs

These are the website technologies, by industry, used by Leads Biolabs top domains

Widget (2)

General Captcha

Advertising (1)

PubMatic

Mobile (1)

Meta Viewport

Other (1)

Google API

More Technologies

1

See all

News & Signals from Leads Biolabs

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsDianthustx partnered with Nanjing Leads Biolabs Co.,Ltd on Oct 1st '25.Beyond claseprubart, Dianthus added a second clinical-stage asset through an October 2025 exclusive licensing agreement with Nanjing Leads Biolabs.

NewsNanjing Leads Biolabs Co.,Ltd is developing LBL-051 on Nov 7th '24.On Nov. 7, 2024, Aditum Bio and Leads Biolabs announced that they have formed a new company, Oblenio Bio, in conjunction with an exclusive option and license agreement the companies have entered into to develop LBL-051, a first-in-class CD19xB-cell maturation antigen (BCMA)xCD3 tri-specific T-cell engager antibody, for treating autoimmune diseases.

NewsNanjing Leads Biolabs Co.,Ltd is developing tri-specific t-cell engager for autoimmune disorders.Aditum Bio and Leads Biolabs announce the formation of Oblenio Bio to develop a tri-specific t-cell engager for autoimmune disorders.